Development Pipeline

An Established Platform. Multiple Disease Applications.

Kivara is actively advancing two flagship programs — NeuroIntercept™ AD and NeuroIntercept™ MS — built on the established Intercept IQ™ platform and designed to expand across the broader neurodegenerative landscape.

Active Programs Pipeline Overview

Molecular diagnostics visualization featuring DNA, neural pathways, and biomarker signatures

Active Development

Two Flagship Programs. One Proven Platform.

NeuroIntercept™ AD and NeuroIntercept™ MS are both in active development, leveraging the established Intercept IQ™ platform to advance earlier detection across Alzheimer's disease and Multiple Sclerosis.

KIV-AD

NeuroIntercept™ AD

Alzheimer's Disease

Active

A next-generation blood-based diagnostic program integrating cell-free DNA analysis, epigenetic profiling, AI, and multi-omic analytics to detect molecular signals of Alzheimer's biology years before clinical symptoms emerge.

Cell-free DNA
Epigenetic profiling
Amyloid biology
Tau-related stress
Synaptic integrity
AI-driven analytics

Current Stage

Assay & Biomarker Discovery

Development Timeline

Platform Technology Established
Complete
Assay & Biomarker Discovery
Current
Clinical Partner Recruitment & Biobank Development
Prospective Biobank Studies
Actively Enrolling Clinical Studies
Clinical Validation
Regulatory Strategy

KIV-MS

NeuroIntercept™ MS

Multiple Sclerosis

Active

NeuroIntercept™ MS is being developed as a next-generation blood-based molecular diagnostic designed to identify biological signals associated with Multiple Sclerosis at the earliest possible stages. Built on the proprietary Intercept IQ™ platform, the program integrates biomarker discovery, artificial intelligence, and precision molecular analysis to support earlier detection and future disease monitoring.

Myelin integrity
Neuroinflammation
Axonal injury
Cell-free DNA
AI-driven analytics
Disease monitoring

Current Stage

Clinical Partner Recruitment & Biobank Development

Development Timeline

Platform Technology Established
Complete
Assay & Biomarker Discovery
Complete
Clinical Partner Recruitment & Biobank Development
Current
Prospective Biobank Studies
Actively Enrolling Clinical Studies
Clinical Validation
Regulatory Strategy

Kivara translational research team reviewing the molecular diagnostics program roadmap

Pipeline Overview

Expanding the Intercept IQ™ Platform

One molecular diagnostics platform, designed to scale. The same scientific and computational foundation powering our active programs is engineered to extend across additional neurodegenerative diseases over time.

Intercept IQ™ Platform

Intercept IQ™

Active Programs

NeuroIntercept™ AD

Alzheimer's Disease

Active

NeuroIntercept™ MS

Multiple Sclerosis

Active

Future Expansion

NeuroIntercept™ PD

Parkinson's Disease

Future

Frontotemporal Dementia

FTD spectrum

Future

Lewy Body Dementia

Synucleinopathies

Future

Additional Neurodegenerative Diseases

Platform expansion

Future

Our Vision

Building the Future of Early Neurodegenerative Disease Detection

Kivara Neurosciences is developing a scalable molecular diagnostics platform designed to identify the earliest biological signals of neurodegenerative disease. By combining blood-based biomarkers, artificial intelligence, and precision molecular analysis, the Intercept IQ™ platform is designed to expand across multiple neurological conditions over time, creating a unified approach to earlier detection and precision medicine.

Explore the Science Partner With Kivara

Core Platform

Intercept IQ™

NeuroIntercept™ AD

Active

NeuroIntercept™ MS

Active

NeuroIntercept™ PD

Future

FTD / Lewy Body

Future

+ Additional Neurodegenerative Disorders